The Impact of Choice of NNRTI on Short-Term Treatment Outcomes among HIV-Infected Patients Prescribed Tenofovir and Lamivudine in Johannesburg, South Africa

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Shearer, Kate ^a   Fox, Matthew P ^a,b   Maskew, Mhairi ^a   Berhanu, Rebecca ^c   Long, Lawrence ^a   Sanne, Ian ^a,c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c RIGHT TO CARE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; TENOFOVIR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRESCRIPTION; RISK ASSESSMENT; RISK FACTOR; SHORT COURSE THERAPY; SOUTH AFRICA; VIRUS LOAD;

EID: 84881344101     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071719     Document Type: Article

References (24)

1. World Health Organization (2006) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach- 2006 revision.
2. Renaud-Thery F, Nguimfack BD, Vitoria M, Lee E, Graaff P, et al. (2007) Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS 21: S89-S95.
3. Mutimura E, Stewart A, Rheeder P, Crowther NJ, (2007) Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 46: 451-455.
4. Van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, et al. (2007) High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 101: 793-798.
5. Geddes R, Knight S, Moosa MYS, Reddi A, Uebel K, et al. (2006) A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 96: 722-724.
6. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach- 2010 revision.
7. World Health Organization (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010.
8. Lapadula G, Costarelli S, Quiros-Roldan E, Calabresi A, Izzo I, et al. (2008) Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis 46: 1127-1129.
9. Rey D, Hoen B, Chavanet P, Schmitt M, Hoizey G, et al. (2009) High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 63: 380-388.
10. Clotet B, (2008) Once-daily dosing of nevirapine in HAART. J Antimicrob Chemother 61: 13-16.
11. Redfield RR, Morrow JS, (2008) Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine. Clin Infect Dis 47: 984-985.
12. National Department of Health Republic of South Africa (2010) Clinical guidelines for the management of HIV & AIDS in adults and adolescents.
13. Fox MP, Maskew M, Macphail AP, Long L, Brennan AT, et al. (2013) Cohort Profile: The Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol 42: 430-439.
14. National Department of Health Republic of South Africa (2013) The South African Antiretroviral Treatment Guidelines 2013.
15. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, et al. (2008) Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 300: 530-539.
16. Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, et al. (2010) Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 24: 1461-1470.
17. Fox MP, Brennan A, Maskew M, MacPhail P, Sanne I, (2010) Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health 15: 405-413.
18. Zou G, (2004) A Modified Poisson Regression Approach to Prospective Studies with Binary Data. Am J Epidemiol 159: 702-706.
19. Towner W, Kerrigan HL, LaRiviere M, Tsai T, Nomura J, et al. (2004) Efficacy of a once daily (QD) regimen of nevirapine (NVP), lamivudine (3TC) and tenofovir (TDF) in treatment-naive HIV infected patients: a pilot study. 7th Inernational Congress on Drug Therapy in HIV Infection. Glasgow. Abstract P49.
20. Darin K, Scarsi K, Meloni S, H R, Chang C, et al. (2010) Clinical and virologic outcomes of six first-line regimens in a large ART program in Nigeria. 10th International AIDS Conference. Vienna. Abstract THPE0117.
21. Robertson C, Berry A, Mahungu J, Stradling C, Barrett S, et al. (2007) Truvada (TDF + FTC) or TDF + 3TC and once daily nevirapine: individualising patient care with TDM and early intervention is associated with optimal outcomes. 11th European AIDS Conference. Madrid. Abstract P4.2/02.
22. Weberschock T, Gholam P, Hueter E, Flux K, (2009) SWS Study Centers, et al (2009) Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial). Eur J Med Res 14: 516-519.
23. Smith D, Chan D, Maruszak H, Jeganathan S, (2011) Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects. Int J STD AIDS 22: 228-230.
24. Tang MW, Kanki PJ, Shafer RW, (2012) A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis 54: 862-875.